INSUBCONTINENT EXCLUSIVE:
23andMe, Color, and other genomic sequencing startups have exposed demand from consumers for cheap ways to test for potential problems they
and speed that process up, in the same ways that 23andMe and Color have done for consumers
Genoox at its heart is a data science company, taking the raw data from a genome sequencing and figuring out how to convey actionable
hand a patient information based on their genome, but rather target clinical experts that might be able to use that data and better
determine diagnoses for patients
The physician is the one that will have the final say in the decision or diagnosis, and the whole point here is to just take massive amounts
of data and figure out a few points that a physician can use in order to make a better judgment call
And beyond that, Genoox can update those doctors as more and more research comes out regarding the potential health complications a patient
beyond that into other processes like carrier screening or hereditary cancer
This is a strategy that those direct-to-consumer companies are also employing, with Color recently rolling out a test that tries to search
for hereditary risk for heart conditions like arrhythmia
clinical applications or clinical use
I think the technology was kind of proven, along the years, and through some papers we published the question was not about the tech but
Sophia Genetics is also looking to use genomic data and physician input to better diagnose patients, and also raised an additional $30
million in September last year
